Reviewing Chromadex (CDXC) & Heron Therapeutics (HRTX)

Chromadex (NASDAQ: CDXC) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Earnings and Valuation

This table compares Chromadex and Heron Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Chromadex $26.81 million 10.18 -$2.92 million ($0.23) -22.04
Heron Therapeutics $1.28 million 1,034.61 -$173.14 million ($3.79) -5.41

Chromadex has higher revenue and earnings than Heron Therapeutics. Chromadex is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

5.9% of Chromadex shares are owned by institutional investors. Comparatively, 98.4% of Heron Therapeutics shares are owned by institutional investors. 11.6% of Chromadex shares are owned by company insiders. Comparatively, 19.9% of Heron Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Chromadex and Heron Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chromadex 0 0 2 0 3.00
Heron Therapeutics 0 0 10 0 3.00

Chromadex presently has a consensus target price of $7.50, indicating a potential upside of 47.93%. Heron Therapeutics has a consensus target price of $29.90, indicating a potential upside of 45.85%. Given Chromadex’s higher probable upside, equities analysts plainly believe Chromadex is more favorable than Heron Therapeutics.

Volatility and Risk

Chromadex has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500.

Profitability

This table compares Chromadex and Heron Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Chromadex -21.89% -47.30% -32.25%
Heron Therapeutics -831.89% -385.11% -141.39%

Summary

Chromadex beats Heron Therapeutics on 7 of the 13 factors compared between the two stocks.

About Chromadex

Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.

About Heron Therapeutics

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company’s SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply